Journal of neuroimmunology · 2016
Astilbin ameliorates experimental autoimmune myasthenia gravis by decreased Th17 cytokines and up-regulated T regulatory cells.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Meng Qing-Fang, Zhang Zheng, Wang Yan-Jun, Chen Wei, Li Fei-Fei, Yue Long-Tao, Zhang Chang-Jun, Li Heng, Zhang Min, Wang Cong-Cong, Zhang Peng, Chen Hui, Duan Rui-Sheng, Sun Shan-Mei, Li Yan-Bin
Аннотация
Astilbin, a major bioactive compound extracted from Rhizoma smilacis glabrae (RSG), has been reported to possess immunosuppressive properties. Our study first evaluated the effect of astilbin on experimental autoimmune myasthenia gravis (EAMG) in Lewis rats. The results showed that astilbin could attenuate the severity of EAMG by decreasing antigen-specific autoantibodies with up-regulation of regulatory T cells and down-regulation of Th17 cells. In addition to, astilbin also reduced the efficiency of the antigen presenting cells on which the expression of MHC class II decreased. These results suggest that astilbin might be a candidate drug for immunoregulation of EAMG, and provide us new treatment ideas for human myasthenia gravis (MG).
Предметные рубрики MeSH
Analysis of VarianceAnimalsAnti-Inflammatory AgentsAntigens, CDBody WeightCell ProliferationCytokinesDisease Models, AnimalDose-Response Relationship, DrugFemaleFlavonolsFlow CytometryHLA-DR alpha-ChainsMyasthenia Gravis, Autoimmune, ExperimentalRatsRats, Inbred LewSincalideT-Lymphocytes, RegulatoryTh17 Cells